Neuralink’s disclosure last week that tiny wires inside the brain of its first patient had pulled out of position is an issue the Elon Musk company has known about for years, according to five people familiar with the matter.

The company knew from animal testing it had conducted ahead of its U.S. approval last year that the wires might retract, removing with them the sensitive electrodes that decode brain signals, three of the sources said. Neuralink deemed the risk low enough for a redesign not to be merited, the sources added.

The company said last week that the implant’s tiny wires, which are thinner than a human hair, retracted from a patient’s brain in its first human trial, resulting in fewer electrodes that could measure brain signals.

  • ZapBeebz_@lemmy.world
    link
    fedilink
    arrow-up
    2
    ·
    6 months ago

    It’s a lot easier to warranty a phone screen than it is brain surgery. That’s why that expectation was acceptable for screens.

    • FlowVoid@lemmy.world
      link
      fedilink
      English
      arrow-up
      2
      arrow-down
      1
      ·
      6 months ago

      By the same token, medical devices have more built-in redundancies in case of partial failure. That’s why the overall impact on the patient is more important than how many electrodes are operational.

      • ZapBeebz_@lemmy.world
        link
        fedilink
        arrow-up
        3
        ·
        6 months ago

        I will admit, I think I’m coming from a place of zero trust that anything musk has his hands in has any amount of safety or redundancy built in, because that might hurt the bottom line

        • FlowVoid@lemmy.world
          link
          fedilink
          English
          arrow-up
          2
          arrow-down
          1
          ·
          6 months ago

          Pretty much every medical device is made by people who are equally interested in the bottom line, they just aren’t constantly in the media spotlight like Musk.

          Fortunately there are government agencies that closely watch these companies to make sure patient safety comes first.